|
|
Founding of Innogenetics NV on July 18, 1985 by Rudi Mariën and Hugo Van Heuverswijn. |
|
|
Discovery of HIV-1 group O variant, a key discovery in HIV diagnostics. |
|
|
Start of HCV genotyping leading to discovery of more than 50 HCV subtypes by 1995. |
|
|
Launch of first commercial tests for cystic fibrosis in Europe (INNO-LiPA CFTR). |
|
|
Launch of first commercial test for HCV genotyping worldwide (INNO-LiPA HCV). |
|
|
Launch of world’s first commercial Alzheimer’s disease research test for hTau (INNOTEST® hTau Ag).
|
|
|
First biotech company listed on high-tech EASDAQ stock exchange. |
|
|
Launch of world’s first commercial Alzheimer’s disease research test for ß-AMYLOID (INNOTEST® ß-AMYLOID(1-42)).
|
|
|
Launch of world’s first commercial test for HBV genotyping (INNO-LiPA HBV Genotyping).
Launch of world’s first commercial Alzheimer’s Disease research test for phospho-tau
(INNOTEST® PHOSPHO-TAU(181p)). |
|
|
First company to enter Phase IIb development for an HCV therapeutic vaccine candidate. |
|
|
Acquisition of therapeutic vaccine program of Genencor International Inc.
Partnership with PamGene International BV to develop Innogenetics' new generation multiparameter platform.
|
|
|
Securing of full PCR license from F. Hoffman-La Roche Ltd. |
|
|
Innogenetics and Third Wave Technologies Inc. resolve patent suit in field of HCV genotyping.
HPV genotyping test ready for CE-marked and launch.
Start Innogenetics – sanofi-aventis collaboration in field of Alzheimer’s disease.
|
|
|
U.S. Court of Appeals reinstates permanent injunction against Abbott Laboratories for infringing Innogenetics’ patent.
Research results for first Alzheimer biomarker test in blood presented.
Therapeutics activities transferred into a wholly owned subsidiary, GENimmune NV.
Settlement and licensing agreement in the field of hepatitis C diagnostics.
|
|
2008
|
Innogenetics announced its intention to restructure GENimmune NV
Settlement and licensing agreement with Abbott Laboratories in the field of hepatitis C genotyping.
Friendly bid of Solvay Pharmaceuticals SA to acquire Innogenetics.
Definitive closure of GENimmune NV.
License agreement with GlaxoSmithKline Biologicals for the use of Innogenetics' HPV SPF10 genotyping technology.
|